Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
United Therapeutics Corporation UTHR
$212.72
-$0.76 (-0.36%)
На 18:00, 12 мая 2023
+27.22%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
9942290628.00000000
-
week52high
283.09
-
week52low
178.74
-
Revenue
1936300000
-
P/E TTM
14
-
Beta
0.59619300
-
EPS
14.33000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 12:30
Описание компании
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wedbush | Outperform | Outperform | 24 мая 2022 г. |
| JP Morgan | Overweight | Overweight | 24 мая 2022 г. |
| Jefferies | Buy | Buy | 24 мая 2022 г. |
| Credit Suisse | Outperform | Outperform | 24 мая 2022 г. |
| JP Morgan | Overweight | Overweight | 19 апр 2022 г. |
| Morgan Stanley | Overweight | 11 окт 2022 г. | |
| Oppenheimer | Outperform | Outperform | 03 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 03 ноя 2022 г. |
| JP Morgan | Overweight | Overweight | 03 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 ноя 2022 г. |
| UBS | Buy | 06 дек 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 06 дек 2022 г. |
| Goldman Sachs | Sell | 05 дек 2022 г. | |
| Argus Research | Buy | Buy | 11 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ROTHBLATT MARTINE A | D | 488000 | 8000 | 02 февр 2023 г. |
| ROTHBLATT MARTINE A | D | 130 | 509 | 02 февр 2023 г. |
| ROTHBLATT MARTINE A | D | 639 | 530 | 02 февр 2023 г. |
| ROTHBLATT MARTINE A | D | 1169 | 2122 | 02 февр 2023 г. |
| ROTHBLATT MARTINE A | D | 3291 | 2230 | 02 февр 2023 г. |
| ROTHBLATT MARTINE A | D | 5521 | 1270 | 02 февр 2023 г. |
| ROTHBLATT MARTINE A | D | 6791 | 829 | 02 февр 2023 г. |
| ROTHBLATT MARTINE A | D | 7620 | 510 | 02 февр 2023 г. |
| ROTHBLATT MARTINE A | A | 8130 | 8000 | 02 февр 2023 г. |
| MAHON PAUL A | D | 62500 | 6000 | 02 февр 2023 г. |
Новостная лента
United Therapeutics (UTHR) Q1 Earnings Beat Estimates
Zacks Investment Research
03 мая 2023 г. в 08:22
United Therapeutics (UTHR) came out with quarterly earnings of $4.86 per share, beating the Zacks Consensus Estimate of $4.35 per share. This compares to earnings of $5.03 per share a year ago.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
Zacks Investment Research
02 мая 2023 г. в 14:32
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023
Business Wire
26 апр 2023 г. в 06:00
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. United Therapeutics will host a public webcast Wednesday, May 3, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be avail.
7 Biotech Stocks That Could Cure Your Portfolio Woes
InvestorPlace
19 апр 2023 г. в 19:22
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).
These Are the Top 10 Holdings of Avoro Capital Advisors
24/7 Wall Street
17 апр 2023 г. в 22:54
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.